GlassScriptPhysician profile
David Zweiback
NPI 1457369233
$2,266.97
in general payments reported to CMS, 2019-2025
36 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $11.51 · 2021: $78.10 · 2022: $126 · 2023: $300 · 2024: $504 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.66 | 2020-2025 | Qulipta, Skyrizi, Ubrelvy |
| Lilly USA, LLC | $193.29 | 2019-2025 | Mounjaro, Zepbound, Olumiant |
| Collegium Pharmaceutical, INC. | $166.08 | 2019-2025 | Xtampza, Belbuca |
| Novo Nordisk INC | $163.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $155.31 | 2019 | |
| Axsome Therapeutics, INC. | $142.97 | 2023-2024 | Auvelity |
| Fidia Pharma USA INC. | $140.68 | 2023-2025 | Hyalgan |
| Pfizer INC. | $134.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $112.05 | 2019-2025 | |
| Gilead Sciences, INC. | $97.93 | 2024-2025 | |
| Amgen INC. | $72.11 | 2019-2025 | Evenity, Prolia |
| Genzyme Corporation | $51.53 | 2021-2023 | |
| Janssen Biotech, INC. | $45.83 | 2019 | |
| Idorsia Pharmaceuticals US INC | $40.93 | 2023-2024 | Quviviq |
| Celgene Corporation | $39.62 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zweiback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.